Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy

Browse trials for

• Breast Neoplasms 12,544
• Recurrence 4,279

Keywords

• estrogen receptor
• HER-2
• PgR
• stage II breast cancer
• stage IIIA breast cancer
• stage IIIB breast cancer

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 900 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Lead sponsor

Eastern Cooperative Oncology Group is the lead sponsor of 173 studies on the registry; 7 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.

Eligibility criteria

Interventions

• Geneticmicroarray analysis
• Geneticprotein expression analysis
• Otherimmunohistochemistry staining method
• Otherlaboratory biomarker analysis

Primary outcomes

1. Distant, local/regional, and ipsilateral breast relapse

2. First breast cancer recurrence

3. Relapse-free interval

Secondary outcomes

1. Distant involvement at time of first recurrence

2. Disease-free survival

3. Overall survival

Publications

• Badve SS, Baehner FL, Gray R, et al.: ER and PR assessment in ECOG 2197: comparison of locally determined IHC with centrally determined IHC and quantitative RT-PCR. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-87, 2007.
• Sparano JA, Goldstein L, Childs B, et al.: Association of individual genes with risk of relapse in operable breast cancer: analysis of E2197. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-27, 2007.